AU2012319239B2 - Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds - Google Patents

Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds Download PDF

Info

Publication number
AU2012319239B2
AU2012319239B2 AU2012319239A AU2012319239A AU2012319239B2 AU 2012319239 B2 AU2012319239 B2 AU 2012319239B2 AU 2012319239 A AU2012319239 A AU 2012319239A AU 2012319239 A AU2012319239 A AU 2012319239A AU 2012319239 B2 AU2012319239 B2 AU 2012319239B2
Authority
AU
Australia
Prior art keywords
nanoparticles
quillaja
cells
saponin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012319239A
Other languages
English (en)
Other versions
AU2012319239A1 (en
Inventor
Saideh Berenjian
Kafei Hu
Bror Morein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mx Adjuvac AB
Original Assignee
Mx Adjuvac AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47143250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012319239(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mx Adjuvac AB filed Critical Mx Adjuvac AB
Publication of AU2012319239A1 publication Critical patent/AU2012319239A1/en
Application granted granted Critical
Publication of AU2012319239B2 publication Critical patent/AU2012319239B2/en
Assigned to MX ADJUVAC AB reassignment MX ADJUVAC AB Request for Assignment Assignors: MOREINX AB
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Alternative & Traditional Medicine (AREA)
AU2012319239A 2011-10-03 2012-10-01 Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds Active AU2012319239B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161542425P 2011-10-03 2011-10-03
US61/542,425 2011-10-03
PCT/SE2012/051048 WO2013051994A1 (en) 2011-10-03 2012-10-01 Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds

Publications (2)

Publication Number Publication Date
AU2012319239A1 AU2012319239A1 (en) 2014-04-03
AU2012319239B2 true AU2012319239B2 (en) 2017-04-20

Family

ID=47143250

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012319239A Active AU2012319239B2 (en) 2011-10-03 2012-10-01 Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds

Country Status (17)

Country Link
US (3) US10047116B2 (enExample)
EP (3) EP4176871A1 (enExample)
JP (1) JP6050822B2 (enExample)
KR (1) KR102090740B1 (enExample)
CN (1) CN103857403B (enExample)
AU (1) AU2012319239B2 (enExample)
CA (1) CA2850296C (enExample)
DK (2) DK2750683T4 (enExample)
ES (1) ES2673957T5 (enExample)
HR (1) HRP20180956T1 (enExample)
IN (1) IN2014DN03485A (enExample)
PL (1) PL2750683T3 (enExample)
PT (1) PT2750683T (enExample)
RS (1) RS57350B1 (enExample)
TR (1) TR201808733T4 (enExample)
WO (1) WO2013051994A1 (enExample)
ZA (1) ZA201402040B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2750683T4 (da) * 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
EP2777402A1 (en) 2013-03-15 2014-09-17 DSM IP Assets B.V. Solid lipid nanoparticles (I)
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
CN104382856B (zh) * 2014-12-04 2017-11-14 中国药科大学 一种去氧鬼臼毒素长循环脂质体冻干制剂
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
US11478433B2 (en) 2017-06-23 2022-10-25 Yale University Nanomaterials with enhanced drug delivery efficiency
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
EP3669890A1 (en) * 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
JP7597554B2 (ja) * 2020-10-30 2024-12-10 株式会社ニップン オキシトシン受容体作動性組成物
CN116077639A (zh) * 2023-01-05 2023-05-09 国药中生生物技术研究院有限公司 雷公藤红素或其可药用衍生物在制备疫苗佐剂中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679354A (en) * 1988-09-30 1997-10-21 Morein; Bror Matrix with immunomodulating activity
WO2009156960A2 (en) * 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
US3803124A (en) 1968-04-12 1974-04-09 Farmaceutici It Soc Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
GB1235022A (en) 1969-06-04 1971-06-09 Laeaeke Ag A new method for the production of cyclophosphamide
DE2124023C3 (de) 1970-05-27 1980-07-10 Richter Gedeon Vegyeszeti Gyar R.T., Budapest Verfahren zur selektiven Gewinnung von Vinblastin, Vinleurosin und Vincristin oder von deren Sulfaten
US4020270A (en) 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative
GB1467383A (en) 1974-06-12 1977-03-16 Farmaceutici Italia Daunomycin analogues
US4307100A (en) 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
DE2845574A1 (de) 1978-10-19 1980-04-24 Deutsches Krebsforsch Durch heterocyclische ringe oder alkylreste substituierte analoga von ccnu und verfahren zu deren herstellung
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
EP0111058B1 (en) 1982-11-26 1987-11-04 Nippon Kayaku Kabushiki Kaisha Process for producing 4'-demethyl-epipodophyllotoxin-beta-d-ethylidene-glucoside and acyl-derivative thereof
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ES2039229T3 (es) * 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0679958B2 (ja) 1988-10-07 1994-10-12 東レ株式会社 糸条の巻取装置
GB8919819D0 (en) 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
IT1250692B (it) 1991-07-23 1995-04-21 Procedimento per la preparazione di demetilepipodofillotossina- beta-d-glucosidi.
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9719426D0 (en) 1997-09-13 1997-11-12 Johnson Matthey Plc Novel process
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE59903869D1 (de) * 1998-10-14 2003-01-30 Cognis Deutschland Gmbh Verwendung von nanoskaligen sterolen und sterolestern
SI1650221T1 (sl) * 2000-02-23 2012-09-28 Glaxosmithkline Biolog Sa Nove spojine
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
DE60229118D1 (de) 2001-04-04 2008-11-13 Nordic Vaccine Technology As Polynukleotide-bindende komplexe die sterolen und saponine enthalten
WO2002102311A2 (en) * 2001-06-15 2002-12-27 Cornerstone Pharmaceuticals Nanoparticles for treating targeted tissues and cells
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
US7482018B2 (en) * 2001-12-21 2009-01-27 Soane Family Trust Use of oligomers and polymers for drug solubilization, stabilization, and delivery
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
JP2006503072A (ja) 2002-10-02 2006-01-26 ノルディック ワクチン テクノロジー アクティーゼルスカブ ワクチン接種用組成物
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US20050175623A1 (en) * 2004-02-10 2005-08-11 Zheng-Pin Wang Saponins as anticancer agent
US20080194494A1 (en) * 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
KR100641060B1 (ko) * 2005-07-22 2006-11-01 삼성전자주식회사 게이트 구조물의 제조 방법 및 이를 이용하는 반도체장치의 제조 방법
DE102006007903A1 (de) 2005-12-21 2007-07-05 VD-Werkstätten GmbH & Co KG Verfahren für die Herstellung von Möbel-Formteilen
CA2637194A1 (en) * 2006-01-18 2007-07-26 National University Corporation Tokyo Medical And Dental University Biomaterial for osteogenesis containing osteogenesis promoter and nanogel
CN101563090B (zh) * 2006-11-20 2013-01-02 杜科姆公司 包含南美皂皮树皂苷的含脂质颗粒用于治疗癌症的用途
CN101848702B (zh) * 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
JP2010514431A (ja) * 2006-12-29 2010-05-06 エボニック デグサ ゲーエムベーハー 生成物阻害が低減されたメチオニンシンターゼ
US20080311045A1 (en) * 2007-06-06 2008-12-18 Biovaluation & Analysis, Inc. Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
MX2010003642A (es) * 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
SG185294A1 (en) * 2007-10-12 2012-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
WO2010023216A1 (en) * 2008-08-28 2010-03-04 Glaxosmithkline Biologicals S.A. Vaccine
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
PL2445526T3 (pl) * 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
SG176807A1 (en) * 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
CN102470168A (zh) 2009-07-10 2012-05-23 伊斯克诺瓦公司 新组合物
JP5833145B2 (ja) * 2011-02-04 2015-12-16 ゾエティス・エルエルシー 免疫原性ｂｏｒｄｅｔｅｌｌａｂｒｏｎｃｈｉｓｅｐｔｉｃａ組成物
JP2014519496A (ja) * 2011-05-11 2014-08-14 ナノヴァレント ファーマシューティカルズ，インコーポレイテッド Ａｌｃａｍ細胞表面受容体を標的とする細胞毒性重合リポソームナノ粒子による増強された骨肉腫の増殖抑制
DK2750683T4 (da) * 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
GB201119999D0 (en) * 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
CN110418593B (zh) 2017-10-20 2022-04-19 科亚列士信荣株式会社 半成品卷制造装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679354A (en) * 1988-09-30 1997-10-21 Morein; Bror Matrix with immunomodulating activity
WO2009156960A2 (en) * 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions

Also Published As

Publication number Publication date
PT2750683T (pt) 2018-06-26
ZA201402040B (en) 2016-01-27
JP6050822B2 (ja) 2016-12-21
DK2750683T3 (en) 2018-07-02
DK2750683T4 (da) 2021-04-12
US20140234349A1 (en) 2014-08-21
RS57350B1 (sr) 2018-08-31
TR201808733T4 (tr) 2018-07-23
CN103857403B (zh) 2019-04-12
IN2014DN03485A (enExample) 2015-06-05
DK3311827T3 (da) 2023-04-03
US10487107B2 (en) 2019-11-26
EP3311827A1 (en) 2018-04-25
CA2850296A1 (en) 2013-04-11
US20180327443A1 (en) 2018-11-15
US20170260224A1 (en) 2017-09-14
WO2013051994A1 (en) 2013-04-11
CA2850296C (en) 2021-01-12
AU2012319239A1 (en) 2014-04-03
US10047116B2 (en) 2018-08-14
KR102090740B1 (ko) 2020-03-18
EP2750683A1 (en) 2014-07-09
CN103857403A (zh) 2014-06-11
EP4176871A1 (en) 2023-05-10
ES2673957T5 (es) 2021-12-15
US10100078B2 (en) 2018-10-16
EP3311827B1 (en) 2023-01-04
ES2673957T3 (es) 2018-06-26
EP2750683B2 (en) 2021-01-06
JP2014530219A (ja) 2014-11-17
KR20140084113A (ko) 2014-07-04
PL2750683T3 (pl) 2018-10-31
HRP20180956T1 (hr) 2018-08-24
EP2750683B1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
US10487107B2 (en) Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
US9907846B2 (en) Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
Aqil et al. Exosomal formulation enhances therapeutic response of celastrol against lung cancer
Yue et al. Combined therapy using bevacizumab and turmeric ethanolic extract (with absorbable curcumin) exhibited beneficial efficacy in colon cancer mice
EP2094278B1 (en) Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
Liu et al. Preparation, characterization, and evaluation of antitumor effect of Brucea javanica oil cationic nanoemulsions
US20240238214A1 (en) Nanoconstructs and nanoparticle-mediated delivery of immunogenic cell death inducers for enhancing cancer immunotherapy
CN116617386B (zh) 雷公藤红素或其可药用衍生物在制备疫苗佐剂中的用途
Huang et al. PEGylated nano-Rehmannia glutinosa polysaccharide induces potent adaptive immunity against Bordetella bronchiseptica
Hamid et al. A novel cationic liposome-formulated toll like receptor (TLR) 7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity
JP2022514276A (ja) ワクチンアジュバント効果を有するフィラメント状ナノ粒子
WO2019071031A1 (en) EXOSOMAL ADMINISTRATION OF ANTHOCYANIDINES AND CURCUMIN
Hamulati et al. Development of a total flavonoids extract of Artemisia Rupestris L. via nanotechnology and its antiviral effect in vitro
Al-Harrasi et al. Role of Drug Repurposing and Natural Products
US20150182470A1 (en) Reconstituted apolipoprotein b lipoparticle, a preparation method and uses thereof
CN120983615A (zh) 基于分枝杆菌脂质提取物的疫苗或药物组合物、制备及其应用
JP2021123582A (ja) 効率的な抗原の細胞内送達とアジュバント活性を有する化合物を有効成分とする薬剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MX ADJUVAC AB

Free format text: FORMER OWNER(S): MOREINX AB